DOI: 10.1055/s-00000030

Der Klinikarzt

LinksSchließen

Referenz

Duffaud F, Blay JY, Mir O. et al.
Results of randomized, placebo (PL)-controlled phase II study evaluating efficacy and safety of regorafenib (REG) in patients (pts) with metastatic osteosarcoma (metOS), on behalf of the French Sarcoma Group (FSG) and Unicancer.
ASCO. 2018 Abstract #11504

Bibliographische Angaben herunterladen

Aufrufen in: